Health-related quality of life assessment using KBILD in fibrotic interstitial lung diseases receiving antifibrotic therapy: a prospective longitudinal study
14 affiliations
- 1Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
- 2Department of Respiratory Medicine, Seirei-Hamamatsu General Hospital, Hamamatsu, Japan
- 3Department of Respiratory Medicine, Iwata City Hospital, Hamamatsu, Japan
- 4Department of Respiratory Medicine, Seirei-Mikatahara General Hospital, Hamamatsu, Japan
- 5Department of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
- 6Department of Respiratory Medicine, Fujieda City Hospital, Fujieda, Japan
- 7Department of Respiratory Medicine, Hamamatsu Rosai Hospital, Shizuoka, Japan
- 8Department of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan
- 9Department Respiratory Medicine, Tenryu Hospital, National Hospital Organization, Hamamatsu, Japan
- 10Department Respiratory Medicine, Shizuoka Saiseikai General Hospital, Shizuoka, Japan
- 11Department Respiratory Medicine, Hamamatsu Medical Center, Hamamatsu, Japan
- 12Department of Respiratory Medicine, JA Shizuoka Kohseiren Enshu Hospital, Hamamatsu, Japan
- 13Department of Respiratory Medicine, Shizuoka Red Cross Hospital, Shizuoka, Japan
- 14Department of Respiratory Medicine, Shizuoka City Shimizu Hospital, Shimizu, Japan
Abstract
Background: Patients with fibrotic interstitial lung diseases (ILDs) experience impaired health-related quality of life (HRQoL). The King's Brief Interstitial Lung Disease (KBILD) questionnaire was designed to evaluate disease-specific HRQoL; however, its practical application in real-world clinical settings has not been thoroughly investigated.
Methods: This prospective longitudinal study included 289 patients with fibrotic ILD initiated antifibrotic therapy. Their HRQoL was evaluated using the KBILD questionnaire at baseline, 6 months and 1 year. A total of 289, 164 and 159 patients completed the KBILD assessment at the aforementioned time points, respectively. The associations between the KBILD scores, clinical parameters and mortality risk were evaluated.
Results: The KBILD Total score demonstrated a moderate correlation with dyspnoea scale but a weak or no correlation with pulmonary function test parameters and ILD aetiology. Interestingly, more than 20% of the patients showed significant improvement (≥5 points) at 6 months and 1 year. A lower baseline KBILD Total score was associated with disease progression and reduced survival, independent of the ILD–gender–age–physiology index. In addition, longitudinal assessment showed that the cross-sectional KBILD Total score at 6 months and 1 year and longitudinal decreases in the KBILD Total score at 1 year were associated with increased mortality risk.
Conclusion: Antifibrotic therapy has a positive impact on HRQoL in a subset of patients with fibrotic ILDs. Repeated KBILD assessment may aid in monitoring mortality risk, independent of lung function tests.
Related
- Longitudinal Association Between the Change in Serum Procollagen Type III N-Terminal Peptide (PIIINP) and Skeletal Muscle Loss in Patients with Gastrointestinal Cancer Receiving Chemotherapy: A Prospective Cohort Study
- Impact of Tiered Service Delivery Model on Antifibrotic Adherence and Outcomes Among Patients With Interstitial Lung Disease
- Radiofrequency Echographic Multi-Spectrometry for bone health assessment in prostate cancer patients receiving Androgen deprivation therapy: A prospective comparative observational study
- Association between triglyceride-glucose index and all-cause mortality in non-diabetic patients with fibrotic lung disease receiving antifibrotic therapy: A retrospective cohort study
- Prospective Longitudinal Assessment of Central Hemodynamic Profile in Normotensive, Hypertensive and Preeclamptic Women in Pregnancy and Postpartum
BibTeX
@article{suzuki2026healthrelated,
title = {{Health-related quality of life assessment using KBILD in fibrotic interstitial lung diseases receiving antifibrotic therapy: a prospective longitudinal study}},
author = {Yuzo Suzuki and Masato Kono and Sayomi Matsushima and Shinpei Kato and Kosuke Suzuki and Kazuki Tanaka and Keigo Koda and Toshihiro Masuda and Miho Kanai and Masaki Ikeda and Mitsuru Niwa and Yusuke Kaida and Hiroyuki Matsuda and Masanori Harada and Dai Hashimoto and Kazuhiro Asada and Koshi Yokomura and Mikio Toyoshima and Kazutaka Mori and Yusuke Inoue and Hideki Yasui and Hironao Hozumi and Masato Karayama and Kazuki Furuhashi and Noriyuki Enomoto and Tomoyuki Fujisawa and Naoki Inui and Takafumi Suda},
journal = {ERJ Open Research},
year = {2026},
month = sep,
doi = {10.1183/23120541.00402-2026},
url = {https://doi.org/10.1183/23120541.00402-2026},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Health-related quality of life assessment using KBILD in fibrotic interstitial lung diseases receiving antifibrotic therapy: a prospective longitudinal study
AU - Yuzo Suzuki
AU - Masato Kono
AU - Sayomi Matsushima
AU - Shinpei Kato
AU - Kosuke Suzuki
AU - Kazuki Tanaka
AU - Keigo Koda
AU - Toshihiro Masuda
AU - Miho Kanai
AU - Masaki Ikeda
AU - Mitsuru Niwa
AU - Yusuke Kaida
AU - Hiroyuki Matsuda
AU - Masanori Harada
AU - Dai Hashimoto
AU - Kazuhiro Asada
AU - Koshi Yokomura
AU - Mikio Toyoshima
AU - Kazutaka Mori
AU - Yusuke Inoue
AU - Hideki Yasui
AU - Hironao Hozumi
AU - Masato Karayama
AU - Kazuki Furuhashi
AU - Noriyuki Enomoto
AU - Tomoyuki Fujisawa
AU - Naoki Inui
AU - Takafumi Suda
PY - 2026
DA - 2026/09/01
JO - ERJ Open Research
DO - 10.1183/23120541.00402-2026
UR - https://doi.org/10.1183/23120541.00402-2026
AB - Background: Patients with fibrotic interstitial lung diseases (ILDs) experience impaired health-related quality of life (HRQoL). The King's Brief Interstitial Lung Disease (KBILD) questionnaire was designed to evaluate disease-specific HRQoL; however, its practical application in real-world clinical settings has not been thoroughly investigated. Methods: This prospective longitudinal study included 289 patients with fibrotic ILD initiated antifibrotic therapy. Their HRQoL was evaluated using the KBILD questionnaire at baseline, 6 months and 1 year. A total of 289, 164 and 159 patients completed the KBILD assessment at the aforementioned time points, respectively. The associations between the KBILD scores, clinical parameters and mortality risk were evaluated. Results: The KBILD Total score demonstrated a moderate correlation with dyspnoea scale but a weak or no correlation with pulmonary function test parameters and ILD aetiology. Interestingly, more than 20% of the patients showed significant improvement (≥5 points) at 6 months and 1 year. A lower baseline KBILD Total score was associated with disease progression and reduced survival, independent of the ILD–gender–age–physiology index. In addition, longitudinal assessment showed that the cross-sectional KBILD Total score at 6 months and 1 year and longitudinal decreases in the KBILD Total score at 1 year were associated with increased mortality risk. Conclusion: Antifibrotic therapy has a positive impact on HRQoL in a subset of patients with fibrotic ILDs. Repeated KBILD assessment may aid in monitoring mortality risk, independent of lung function tests.
SN - 2312-0541
ER -